The London COPD Exacerbation Cohort

Relationship Between Patient Phenotypes and Exacerbations in Chronic Obstructive Pulmonary Disease.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02755974

Acronym

EXCEL_Cohort

Enrollment

300

Registered

2016-04-29

Start date

2009-01-31

Completion date

2026-12-31

Last updated

2022-06-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Disease, Chronic Obstructive

Keywords

Chronic Obstructive Pulmonary Disease

Brief summary

The London COPD exacerbation (EXCEL) cohort builds on an established cohort started in 1995 and designed to study COPD exacerbations and their impact on health-status and disease progression.

Detailed description

Our intentions are to phenotype Chronic Obstructive Pulmonary Disease (COPD) patients on the basis of factors that a related to (a) exacerbation frequency which will include (b) lung function to assess disease severity, (c) baseline therapy, (d) airway and systemic inflammatory markers, (e) health status, (f) gene expression, (g) airway bacterial and viral load and (h) co-morbidity including cardiovascular disease, diabetes and psychological disease, (i) psychological factors,(j) mortality, (k) nasal susceptibility to rhinovirus infection, (l) heart rate variability (m) exhaled hydrogen sulphide.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

40 Years to 100 Years

Healthy volunteers

Inclusion criteria

* Forced Expiratory Volume in 1 sec (FEV1)/Forced Vital Capacity (FVC) ratio of \<0.70 * Able and willing to give informed and written consent

Exclusion criteria

* Patients with a history of asthma, bronchiectasis, carcinoma of the bronchus, or other significant respiratory disease were excluded. * Patients on Immunosuppressive medications or with active cancer * Long term steroid therapy * Age \<40 years at recruitment

Design outcomes

Primary

Measure	Time frame	Description
Annual exacerbation rate (number of exacerbations over a 12 month period)	12 months	Definition of an exacerbation * The presence of 2 new symptoms (one of which must be major) for 2 consecutive days * Major symptoms: increased breathlessness (A), increased sputum colour (B1) or increased sputum amount (B2) * Minor symptoms: a cold (C), increased wheeze or chest tightness (D), Sore throat (E1), Increased cough (E2), Fever (F)

Countries

United Kingdom

Contacts

Primary ContactJadwiga A Wedzicha, MD

j.wedzicha@imperial.ac.uk2075947947

Backup ContactGavin C Donaldson, PhD

gavin.donaldson@imperial.ac.uk207 4947859

Outcome results